Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?

Table 7 Major studies of sofosbuvir with other novel direct antiviral agents with or without ribavirin for treatment of hepatitis C virus positive liver transplant recipients reported in 2014

Ref.	n	Patient characteristics	Antiviral scheme	Virological response	SVR	Duration (wk)
Pungpapong et al[85]	55	Fibrosis 3-4 (29%)	SOF + simeprevir ± RBV	98% (EOT)	91%	12
		Decompensated cirrhosis (4%)
		Cholestatic recurrence (15%)
Leroy et al[87] (CUPILT)	21	Fibrosing cholestatic hepatitis	SOF + daclatasvir ± RBV (n = 13)	95% HCV RNA < 15 IU/mL	-	24
			SOF + RBV (n = 6)	81% were not detectable (at week 12 under treatment)
Conti et al[86]	55	Fibrosis 3-4 (33%)	SOF + daclatasvir	85% (at week 8 under treatment)	-	24
		Fibrosing cholestatic hepatitis (7%)
Kwo et al[89] (CORAL I)	34	Fibrosis 0-2	Paritaprevir + ritonavir + ombitasvir + dasabuvir + RBV	100% (EOT)	97%	24
Reddy et al[88]	223	Fibrosis 0-3, CP A-C	SOF + ledipasvir + RBV	-	96%-98% (CP A: 9% CP B: 83%-85% CP C: 60%-67%)	12-24

n: Number of patients included in the study; RBV: Ribavirin; SOF: Sofosbuvir; EOT: End of treatment; SVR: Sustained virological response; CP: Child-Pugh; HCV: Hepatitis C virus.